SCHEMBL25509852

SCHEMBL25509852

CC(C)NC(=O)Nc1ccc(C(C)C)c(O)c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 3/20 0.53
▸ CA1 P00915 3/20 0.53
▸ CA2 P00918 3/20 0.53
▸ CA9 Q16790 3/20 0.53
▸ TRPA1 O75762 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ CHRM1 P11229 1/20 0.44
▸ SLC6A2 P23975 1/20 0.44
▸ ADRA1A P35348 1/20 0.44
▸ HTR2B P41595 1/20 0.44
▸ GAA P10253 3/20 0.43
▸ MAPT P10636 1/20 0.43
▸ TSHR P16473 2/20 0.42
▸ RECQL P46063 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ MAPK1 P28482 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23139482 0.85 ALDH1A1 (0.47) CA12CA1CA2CA9TRPA1
SCHEMBL25497034 0.84 TSHR (0.52) CA12CA1CA2CA9GAA
SCHEMBL25509854 0.82 KDM4E (0.54) CA1CA2TRPA1LMNACHRM1
SCHEMBL23139479 0.81 GAA (0.47) TRPA1LMNACHRM1SLC6A2ADRA1A
SCHEMBL25494265 0.81 NPC1 (0.51) TRPA1LMNACHRM1SLC6A2ADRA1A
SCHEMBL25495313 0.80 KMT2A (0.53) CA12CA1CA2CA9TRPA1
SCHEMBL23139488 0.79 SMN1; SMN2 (0.49) TRPA1LMNACHRM1SLC6A2ADRA1A
SCHEMBL13449739 0.78 CA12 (0.70) CA12CA1CA2CA9LMNA
SCHEMBL25494277 0.77 GAA (0.64) CA12CA1CA2CA9TRPA1
SCHEMBL24894114 0.75 CA12 (0.62) CA12CA1CA2CA9LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230158155-A1 Cell Surface Receptor Binding Compounds and Conjugates LYCIA THERAPEUTICS, INC. 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230158155-A1 Cell Surface Receptor Binding Compounds and Conjugates M6PR, ASGR1, IGF2R CA12 1621/4885CA1 3431/4885CA2 3060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback